Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | CCND3 | P30281 | 3/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.30 |
| ▸ | CDK9 | P50750 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.30 |
| ▸ | DRD4 | P21917 | 2/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859032 | 0.81 | MAPK14 (0.35) | MAPK8 | |
| SCHEMBL4854065 | 0.77 | CCNT1 (0.40) | CDK4CCND1CCNE1CDK2CCNT1 | |
| SCHEMBL14158894 | 0.74 | CDK4 (0.33) | CDK4CCND3CCND1CCNE1CDK2 | |
| SCHEMBL4856638 | 0.73 | MAPK13 (0.37) | CDK4CCND1CDK6 | |
| SCHEMBL4857822 | 0.71 | MAPK14 (0.35) | MAPK8 | |
| SCHEMBL4857829 | 0.71 | MAPK14 (0.35) | MAPK8 | |
| SCHEMBL14158808 | 0.68 | CDK4 (0.37) | CDK4CCND3CCND1CCNE1CDK2 | |
| SCHEMBL4854308 | 0.68 | MAPK14 (0.37) | CDK4CCND3CCND1CCNE1CDK2 | |
| SCHEMBL4856042 | 0.67 | MAPK14 (0.37) | — | |
| SCHEMBL4848068 | 0.67 | WEE1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | claimed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | CDK4 665/4885CCND3 2082/4885CCND1 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.